Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Bristol Myers Squibb

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

Benzinga · Oct 10, 2025

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Benzinga · Sep 23, 2025

Mass shooting in central business district shakes Manhattan, leaves at least 4 dead

345 Park Avenue hosts Blackstone, the world’s largest alternative asset manager, the NFL, KPMG, and Bristol Myers Squibb, among others.

Fortune · Jul 29, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga · Jul 14, 2025

DEI is emerging triumphant in shareholder battles across at companies ranging from Coca-Cola to Berkshire Hathaway

Here’s what happened to anti-DEI proposals put before shareholders at several U.S. companies, including Apple, Goldman Sachs, and Costco.

Fortune · May 10, 2025

Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in funding

Why New Jersey is a hub for biotech manufacturing.

Fortune · Mar 24, 2025

People with blood cancer to benefit from innovative new treatment on the NHS

The type of Car T-cell therapy involves taking a patient’s T-cells and modifying them.

Evening Standard · Feb 20, 2025

Read news from The Economist, FT, and more,
with one subscription

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart · Jan 10, 2025

Why This Dividend Stock Just Scored a Rare Upgrade

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

Barchart · Dec 24, 2024

New schizophrenia drug ‘could change the lives of millions of people’

The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

The Independent UK · Sep 27, 2024

Cobenfy Gets FDA Approval: New Drug Offers Novel Treatment Mechanism For Schizophrenia

The new drug Cobenfy promises to revolutionize treatment for schizophrenia with its novel mechanism, the first of its kind in decades.

Medical Daily · Sep 27, 2024

$100-million facility of Bristol Myers Squibb opened in Hyderabad

Bristol Myers Squibb opens new facility in Hyderabad, investing over $100 million to expand global capabilities.

The Hindu · Feb 26, 2024

Bristol Myers Squibb Reports Strong Q4 Results

Bristol Myers Squibb (BMY) reports strong Q4 results, faces biosimilar competition, but shows growth potential.

Senators ask CEOs why their drugs cost so much more in the U.S.

The Senate HELP committee questioned pharmaceutical CEOs about how much more Americans pay for the same drugs sold for less in Canada, Japan and Europe.

WEKU · Feb 8, 2024

Get all your
news in one place.

100's of premium titles.
One news app.

Roll Call · Jan 26, 2024

Merck, Johnson & Johnson CEOs agree to appear before Senate HELP - Roll Call

Two drug company CEOs have agreed to testify before the Senate HELP Committee on drug prices, avoiding a scheduled subpoena vote on Jan. 31.

Barchart · Dec 26, 2023

Nasdaq Posts a Record High on Strength in Chip Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.60%. Stocks on Tuesday settled moderately higher, with the...

Barchart · Dec 26, 2023

Stocks Climb on Strength in Chip Stocks and Energy Companies

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.42%. Stocks this morning are moderately higher in thin holiday...

Barchart · Dec 26, 2023

Markets Today: Stocks Modestly Higher in Thin Holiday Trade

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.09%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.15%. Stock index futures this morning are modestly higher in thin holiday trade, with markets in Europe and parts of Asia closed for Boxing Day. Stocks are supported...

Get all your
news in one place.

100's of premium titles.
One news app.

Bristol Myers Squibb Acquires Karuna Therapeutics in Billion Deal

Bristol Myers Squibb is set to acquire Karuna Therapeutics in a billion deal, expanding its neuroscience portfolio with the promising antipsychotic dru...

The Independent UK · Dec 22, 2023

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

Fortune · Nov 13, 2023

Developing new medicines for everyone, everywhere, equally

The pharmaceutical industry’s role as healer is sorely diminished if we don’t develop medicines fairly for everyone who needs them.

The Guardian - US · Aug 29, 2023

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

Fortune · Jun 9, 2023

Rethinking auditing and transparency in the age of A.I.

In today’s world of increasing disclosures, such as ESG and cybersecurity, the responsibility of the internal audit continues to expand and has become even more critical.

Fortune · Apr 28, 2023

How health care leaders are leveraging technology in a tumultuous economy

Making health care accessible and equitable is the goal.

Fortune · Apr 26, 2023

3 factors driving health care inequality—and ideas for how we can solve it

'The rich get richer, and the poor get poorer. The same is true for health...The underserved get sicker.'

1 2 3

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.